SynthesisLiver international : official journal of the International Association for the Study of the Liver2026
Clinical Outcomes and Non-Invasive Testing in Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Review.
Synthesis in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Clinical Outcomes and Non-Invasive Testing in Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Review.Liver international : official journal of the International Association for the Study of the Liver · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsMetabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis lacks definitive treatments and poses an increasing healthcare burden globally. We undertook a systematic literature review (SLR) to better understand the disease burden in cirrhosis due to MASH.
methodsThe SLR was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and registered with PROSPERO (CRD4202458650). Embase, MEDLINE, and the Cochrane Library were searched for clinical trials, observational studies, and SLRs/meta-analyses published in 2014-2024 in MASH-related cirrhosis. This study focuses on clinical outcomes, including the role of non-invasive tests (NITs) for predicting these outcomes in patients with MASH-related cirrhosis.
resultsFollowing full-text review, 317 studies were considered eligible for inclusion. Studies on transplant-free survival, decompensation events, and hepatocellular carcinoma (HCC) in cirrhosis due to MASH were few and heterogeneous. In patients with MASH and compensated cirrhosis, transplant-free survival was lower in patients with type 2 diabetes (T2D) than in those without. Risks of decompensation increased with factors that included the presence of varices and T2D. Male sex, T2D, and high Child-Turcotte-Pugh score were risk factors for developing HCC. Three studies compared the performance of NITs for predicting liver-related events, including decompensation, but used varying definitions for these outcomes.
conclusionsThis SLR identified data on a range of clinical outcomes in patients with MASH-related cirrhosis. However, there was limited evidence for certain outcomes including the role of prognostic prediction models for liver-related events in this patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.